{"id":543916,"date":"2021-05-19T23:20:02","date_gmt":"2021-05-19T23:20:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=543916"},"modified":"2021-05-19T23:20:02","modified_gmt":"2021-05-19T23:20:02","slug":"myelofibrosis-mf-market-analysis-market-size-epidemiology-leading-companies-and-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/myelofibrosis-mf-market-analysis-market-size-epidemiology-leading-companies-and-therapies-delveinsight_543916.html","title":{"rendered":"Myelofibrosis (MF) Market Analysis, Market Size, Epidemiology, Leading Companies And Therapies | DelveInsight"},"content":{"rendered":"
\"Myelofibrosis<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Myelofibrosis (MF) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Myelofibrosis (MF), historical and forecasted epidemiology as well as the Myelofibrosis (MF) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Myelofibrosis (MF) – Market Insights, Epidemiology, and Market Forecast-2030”<\/strong>.<\/p>\n

DelveInsight’s“Myelofibrosis (MF) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>″ report delivers an in-depth understanding of the Myelofibrosis (MF), historical and forecasted epidemiology as well as the  Myelofibrosis (MF) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    According to the research, Primary Myelofibrosis is a rare condition that affects approximately 1 in 500,000 people worldwide.<\/p>\n<\/li>\n

  2. \n

    According to an organization,  the true incidence of MF is not known but estimated to be approximately 1-1.5\/100,000 people and is likely higher due to underdiagnosing and underreporting. The median age of diagnosis is approximately 65, but MF can be diagnosed in patients of all ages.<\/p>\n<\/li>\n

  3. \n

    Primary myelofibrosis is a chronic blood disorder that affects males and females in equal numbers. It can occur at any age although it usually affects individuals more than 50 years of age.<\/p>\n<\/li>\n

  4. \n

    The median age at diagnosis is approximately 65. The incidence of myelofibrosis is estimated to be 1.5 cases per 100,000 people in the United States. In studies of Northern European countries, the incidence was estimated to be 0.5 cases per 100,000 people.<\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1. Myelofibrosis (MF) market report covers a descriptive overview and comprehensive insight of the Myelofibrosis (MF) epidemiology and Myelofibrosis (MF) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2. The Myelofibrosis (MF) market report provides insights on the current and emerging therapies.<\/p>\n

    3. Myelofibrosis (MF) market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n

    4. The Myelofibrosis (MF) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Myelofibrosis (MF) market.<\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/myelofibrosis-mf-market<\/span><\/a>
    <\/a><\/strong><\/p>\n

    Myelofibrosis (MF): Overview<\/strong><\/p>\n

    Myelofibrosis is an uncommon type of bone marrow cancer that disrupts your body’s normal production of blood cells.<\/p>\n

    Myelofibrosis causes extensive scarring in your bone marrow, leading to severe anemia that can cause weakness and fatigue. It can also cause a low number of blood-clotting cells called platelets, which increases the risk of bleeding. Myelofibrosis often causes an enlarged spleen.<\/p>\n

    Myelofibrosis is considered to be a chronic leukemia — a cancer that affects the blood-forming tissues in the body. Myelofibrosis belongs to a group of diseases called myeloproliferative disorders.<\/p>\n

    The key players involved in the Myelofibrosis (MF) market:<\/a><\/strong><\/p>\n

      \n
    1. \n

      AbbVie, <\/p>\n<\/li>\n

    2. \n

      Celgene, <\/p>\n<\/li>\n

    3. \n

      Suzhou Zelgen Biopharmaceuticals<\/p>\n<\/li>\n

    4. \n

      Imago BioSciences <\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the Myelofibrosis (MF) treatment scenario in the upcoming years:-<\/strong><\/p>\n

      Drug covered<\/strong><\/p>\n

        \n
      1. \n

        Navitoclax<\/p>\n<\/li>\n

      2. \n

        Luspatercept<\/p>\n<\/li>\n

      3. \n

        Jaktinib<\/p>\n<\/li>\n

      4. \n

        IMG-7289<\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/myelofibrosis-mf-market<\/span><\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/p>\n

        2. Executive Summary<\/p>\n

        3. SWOT analysis<\/p>\n

        4. Myelofibrosis (MF) Patient Share (%) Overview at a Glance<\/p>\n

        5. Myelofibrosis (MF) Market Overview at a Glance<\/p>\n

        6. Myelofibrosis (MF) Disease Background and Overview<\/p>\n

        7. Myelofibrosis (MF) Epidemiology and Patient Population<\/p>\n

        8. Country-Specific Patient Population of Myelofibrosis (MF)<\/p>\n

        9. Myelofibrosis (MF) Current Treatment and Medical Practices<\/p>\n

        10. Unmet Needs<\/p>\n

        11. Myelofibrosis (MF) Emerging Therapies<\/p>\n

        12. Myelofibrosis (MF) Market Outlook<\/p>\n

        13. Country-Wise Myelofibrosis (MF) Market Analysis (2017–2030)<\/p>\n

        14. Market Access and Reimbursement of Therapies<\/p>\n

        15. Market drivers<\/p>\n

        16. Market barriers<\/p>\n

        17. Appendix<\/p>\n

        18. Myelofibrosis (MF) Report Methodology<\/p>\n

        19. DelveInsight Capabilities<\/p>\n

        20. Disclaimer<\/p>\n

        21. About DelveInsight<\/p>\n

        Related Reports:<\/strong><\/p>\n

        Myelofibrosis (MF) – Epidemiology Forecast to 2030<\/strong><\/p>\n

        DelveInsight’s ‘Myelofibrosis (MF) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Myelofibrosis (MF) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight’s “Myelofibrosis (MF) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Myelofibrosis (MF), historical and forecasted epidemiology as well as the Myelofibrosis (MF) market trends in the United States, EU5 … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-543916","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543916","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=543916"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543916\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=543916"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=543916"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=543916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}